Apama Medical Completes C Finance to Develop New Balloon Catheter System for Atrial Fibrillation

Release date: 2016-12-01

Apama Medical, a leading medical device company, recently announced that it has completed a total of approximately $13 million in Series C financing to develop a new RF balloon catheter system for the treatment of atrial fibrillation. The company's existing investors Ascension Ventures, Medvance Incubator Partners, ONSET Ventures and Incept LLC are all involved. Apama did not disclose in detail the use of the funds.

The prevalence of clinical interventional treatment of atrial fibrillation is increasing. The current main treatment methods include single-point radiofrequency ablation and balloon catheter ablation. Both treatments have their own advantages and disadvantages. For example, the method can be applied to a variety of atrial fibrillation symptoms, but the required treatment time is relatively long, and balloon catheter ablation can complete the treatment in a short time, but its The treatment range is very narrow compared to radiofrequency ablation.

The new RF balloon catheter system developed by Apama hopes to combine the advantages of both methods. At a recent scientific meeting of the American College of Cardiology, the company published a clinical study with six patients to demonstrate its safety and efficacy. There are currently 18 volunteers receiving this treatment. Company researchers believe that this product can overcome the limitations of the treatment of heart rhythms including blood thinners, medications, and surgery.

Atrial fibrillation is a common type of tachyarrhythmia, and 1% of people over the age of 60 have atrial fibrillation, which increases exponentially with age. Among them, patients with no structural heart disease accounted for 3% to 11%. The Framingham study found that patients with atrial fibrillation had a 1.5 to 1.9-fold higher mortality rate than those without atrial fibrillation. The occurrence of atrial fibrillation is related to age and the type of underlying disease. Hypertension is the most common cardiovascular disease associated with atrial fibrillation. Patients with atrial fibrillation have a significantly increased risk of embolic complications. According to estimates by the US CDC, there are 2.7-6.1 million people in the United States who may have the disease.

Source: Bio Valley

Home Appliance

Guangzhou Zhongzhinan Supply Chain Co.,Ltd. , https://www.gzzhongzhinan.com